fungi,candida

Fluconazole (UK-49858) is a triazole antifungal agent used to treat oropharyngeal candidiasis and cryptococcal meningitis in AIDS.

Embeconazole (R 120758) is a triazole antifungal agent.Embeconazole has strong in vitro activity against clinically important fungi such as Candida, Aspergillus and Cryptococcus neoformans.

1-Decanol inhibits various bacteria and fungi, including Candida albicans, Penicillium, Aspergillus niger, Bacillus subtilis, Propionibacterium, and others.

Undecanal exhibits inhibitory activity against Saccharomyces cerevisiae ATCC, Candida albicans, and fungi, and is widely used in biochemical experiments and drug synthesis research.

Lanoconazole is an antifungal imidazole drug used primarily for the treatment of fungal skin infections that is potent and orally available. It acts by inhibiting the synthesis of ergosterol in fungal cell membranes, increasing the permeability of fungal cell membranes, leading to cell lysis and death. Lanoconazole exhibits potent antifungal activity against a wide range of pathogenic fungi including yeast, dermatophytes, dermatiaceous fungi, dimorphic fungi, Aspergihs spp., and Candida spp..

HDM-IN-1 (Compound A4) is an inhibitor of fungal histone demethylase (HDM) that inhibits H3K27me3 in Cryptococcus neoformans and Candida auris, with IC50 values of 134 nM and 12 nM, respectively. It demonstrates inhibitory activity against these fungi by preventing biofilm and capsule formation, with an MIC80 of 0.5-2 μg mL. Additionally, HDM-IN-1 exhibits antifungal activity in ICR mouse models.

Group II intron-IN-1 (Compound 1) is an inhibitor of fungal Group II introns with an IC50 of 3 μM. It is applicable in research related to infections caused by fungi such as Candida species.

Fluconazole (hydrate) is a triazole antifungal agent used for oral treatment and prevention of both superficial and systemic fungal infections, including but not limited to balanitis, various Candida infections, Cryptococcus infections, dermatomycosis, and fungal infections of the respiratory and urinary tracts. As the hydrate salt form of fluconazole, it exhibits antifungal activity by inhibiting the growth and development of pathogenic fungi, such as Candida species, at minimal inhibitory concentrations often exceeding 100 mg l. Notably, it disrupts the branching and hyphal formation in C. albicans at concentrations as low as 0.3 mg l, indicating its potency compared to other antifungals like miconazole and ketoconazole which are effective at 100-fold lower concentrations. Clinical studies have not shown a significant increase in the risk of most birth defects with oral fluconazole, although there may be an associated risk of tetralogy of Fallot. Its efficacy against Cryptococcus gattii in koalas suggests it may be ineffective as a sole therapeutic agent at a dosage of 10 mg kg orally every 12 h. Toxicity symptoms from overdose can include hallucinations and paranoid behavior.

Dactylfungins A is a novel antifungal antibiotic produced by Dactylaria Parvispora. The antibiotics were active against Candida pseudotropicalis and other fungi, with a MIC value of fewer than 10 micrograms ml.

Dactylfungins B is a novel antifungal antibiotic produced by Dactylaria Parvispora. The antibiotics were active against Candida pseudotropicalis and other fungi, with a MIC value of fewer than 10 micrograms ml.

T-2307 is an antibiotic commonly used against Candida, exhibiting broad-spectrum antifungal activity against most pathogenic fungi in vitro and in vivo. It selectively induces collapse of yeast mitochondrial membrane potential and can be used for invasive fungal infections.

FTR1335 is a CaNMT inhibitor (IC50 = 0.49 nM) with good fungal selectivity. CaNMT inhibitors are fungicidal and show antifungal activity against Candida (especially fluconazole-resistant strains). They function by inhibiting N-myristoyltransferase (NMT), which catalyzes the transfer of a C14 fatty acif from myristoyl-CoA to the N-terminal of glycine in many fungal proteins. Without this process, fungi can die. This process also occurs in humans, and as such selectivity is an important characteristic of these drugs.

Antifungal Agent 53 (A03), a potent Candida albicans CYP51 inhibitor, exhibits antifungal activity by preventing fungi biofilm formation and demonstrates good safety [1].

Antifungal agent 73 (compound A32) effectively combats azole-resistant candidiasis by disrupting the fungal cell wall and membrane, demonstrating potent in vivo activity against pathogenic fungi, including fluconazole-resistant strains [1].